Navigation Links
Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

um during and after ERBITUX therapy is recommended.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of 774 patients with advanced colorectal cancer (mCRC) receiving ERBITUX. There was one case of ILD reported in 796 patients with head and neck cancer receiving ERBITUX in clinical studies.

In clinical studies of ERBITUX, dermatologic toxicities, including acneform rash, skin drying and fissuring, and inflammatory and infectious sequelae (eg, blepharitis, cheilitis, cellulitis, cyst) were reported. In 208 patients receiving ERBITUX + RT, acneform rash was reported in 87% (17% severe) as compared to 10% in 212 patients treated with radiation therapy alone (1% severe). In patients receiving ERBITUX alone, 76% (N=103) experienced acneform rash (1% severe). In patients with mCRC, acneform rash was reported in 89% (686/774) of all treated patients, and was severe in 11% (84/774). Subsequent to the development of severe dermatologic toxicities, complications including S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation.

The safety of ERBITUX in combination with radiation therapy and cisplatin has not been established. Death and serious cardiotoxicity were observed in a single-am trial with ERBITUX, delayed, accelerated (concomitant boost) fractionation radiation therapy, and cisplatin (100 mg/m2) conducted in patients with locally advanced squamous cell carcinoma of the head and neck. Two of 21 patients died, one as a result of pneumonia and one of an unknown cause. Four patients discontinued treatment due to adverse events. Two of these discontinuations were due to cardiac events (myocardial infarction in one patient and arrhythmia, diminished cardiac output, and hypotension in the other patient).

The inci
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:7/28/2014)... BAUDETTE, Minn. , July 28, 2014  ANI ... that the Company plans to release its second quarter ... 2014, before the opening of the U.S. financial markets. ... Investor Relations section of the Company,s website, www.anipharmaceuticals.com ... and Chief Executive Officer, and Charlotte C. Arnold ...
(Date:7/28/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Financial Results and Highlights Conference CallWhen:Monday, August 4 at ... How:Live on the Internet. Simply log onto our website ... the live event, a replay of the webcast will ... . ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
(Date:7/28/2014)... researchers report that an alternative to the traditional handshake ... experiments, the scientists found that clasping hands transferred about ... other than what is known as a fist bump. ... a cultural substitute for the firm gripping of hands. ... of the American Journal of Infection Control . ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... recipe app for iOS, App is available on iTunes for ... first of its kind, Audio Chef allows you to listen ... gourmet cuisine the easy way: simply get out the ingredients ... no need to measure or prepare ingredients ahead of time, ...
(Date:7/28/2014)... meal you,ve ordered at a restaurantor when something ... your brain. , These waves are called ... cellsboth excitatory and inhibitoryplaying together in an orchestrated ... waves have been associated with higher-level brain function, ... to schizophrenia, Alzheimer,s disease, autism, epilepsy and other ...
(Date:7/28/2014)... 28, 2014 UT Southwestern Medical Center cancer ... irreversibly interferes with the activity of a mutated ... , The molecule, SML-8-73-1 (SML), interferes with the ... homolog. The gene produces proteins called K-Ras that ... result in normal cells dividing uncontrollably and turning ...
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
... debate is still on. Is Hormone Replacement Therapy (HRT), good ... caution. The treatment, which targets menopausal women by giving them ... two -edged sword. Its risks such as breast cancer, and ... traumatic menopausal symptoms. This was mainly due to a 2002 ...
... have criticized Prime Minister John Howard for calling for a ... there was no evidence to suggest migrants were responsible for ... Minister Howard had made the suggestion in an interview to ... sharp rise in HIV cases. ,Don Baxter, ...
... forces to perfect a powerful new weapon in the war ... spores. //Their results are published in the prestigious journal Science, ... to use lasers to detect anthrax in real time as ... now,” says Marlan Scully, Distinguished Professor of Physics at Texas ...
... sexually transmitted disease, has become so drug resistant now ... options to treat this serious disease. ,Doctors prescribe ... ofloxacin, and levofloxacin) as a treatment for the disease. ... and Prevention (CDC) says that the sexual disorder-that affects ...
... are now looking at lactate with a much more ... the brain in the immediate //hours after a traumatic ... they are right, it could change how emergency room ... injuries in the first critical hours after injury. ...
... Viagra, Cialis, and Levitra are the answer to their ... a new report from Harvard Medical School, these pills ... pressures that frequently accompany erectile dysfunction (ED). ... man is feeling sexual desire for his partner. If ...
Cached Medicine News:Health News:Hormone Replacement Therapy – To Choose Or No 2Health News:HIV Experts Criticize Australian PM's Suggestion for Ban on Entry of HIV-infected 2Health News:Physicists Unite To Develop Anthrax Detection Method 2Health News:Physicists Unite To Develop Anthrax Detection Method 3Health News:Physicists Unite To Develop Anthrax Detection Method 4Health News:Scientists Concerned About Gonorrhea’s Drug Resistanc 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: